Target Name: TRIM16L
NCBI ID: G147166
Review Report on TRIM16L Target / Biomarker Content of Review Report on TRIM16L Target / Biomarker
TRIM16L
Other Name(s): TR16L_HUMAN | tripartite motif containing 16 like | Tripartite motif protein 70 | Tripartite motif-containing protein 16-like protein | Tripartite motif containing 16 like, transcript variant 1 | Tripartite motif-containing protein 16-like protein (isoform 1) | Tripartite motif-containing protein 70 | Tripartite motif-containing 16-like | TRIM70 | TRIM16L variant 1

TRIM16L: A Protein Implicated in Endoplasmic Reticulum and Cellular Processes

TRIM16L, also known as TR16L-HUMAN, is a protein that is expressed in human tissues and has been shown to play a role in various physiological processes in the body. As a drug target or biomarker, TRIM16L has potential for use in the treatment of various diseases.

The TRIM16L protein is a member of the Tetraspanin family, which are a group of four proteins that are known for their ability to interact with a wide variety of molecules, including proteins, RNA, and small molecules. The TRIM16L protein is characterized by its ability to localize to the endoplasmic reticulum (ER), where it can interact with various cytoplasmic proteins and play a role in the regulation of cellular processes such as protein synthesis, apoptosis, and autophagy.

One of the key functions of TRIM16L is its role in the regulation of endoplasmic reticulum (ER) traffic. The ER is a membrane-wrapped organelle, where many proteins are synthesized and degraded. The TRIM16L protein is known to interact with the protein known as TRIM17, which is also a member of the Tetraspanin family. TRIM17 is involved in the regulation of protein synthesis and degradation in the ER, and it is thought to play a role in the localization of TRIM16L to the ER.

Another function of TRIM16L is its role in the regulation of cellular apoptosis. Apoptosis is a natural process that is involved in the elimination of damaged or dysfunctional cells in the body. The TRIM16L protein is known to play a role in the regulation of apoptosis by interacting with the protein known as Bcl-2. Bcl-2 is a protein that has been shown to play a role in the regulation of apoptosis, and it is thought to be involved in the inhibition of TRIM16L.

In addition to its role in the regulation of ER traffic and apoptosis, TRIM16L has also been shown to play a role in the regulation of protein synthesis and cytoskeletal organization. The TRIM16L protein is known to interact with the protein known as p16INK4a, which is a negative regulator of the gene encoding the protein known as p16INK4a. p16INK4a is thought to play a role in the regulation of cellular processes such as cell growth, apoptosis, and autophagy, and it is thought to be involved in the inhibition of TRIM16L.

TRIM16L has also been shown to play a role in the regulation of stem cell proliferation. The TRIM16L protein is known to interact with the protein known as KLF, which is a gene transcription factor that is involved in the regulation of stem cell proliferation. KLF is thought to play a role in the regulation of cellular processes such as cell growth, apoptosis, and autophagy, and it is thought to be involved in the inhibition of TRIM16L.

In conclusion, TRIM16L is a protein that is involved in various physiological processes in the body. As a drug target or biomarker, TRIM16L has potential for use in the treatment of various diseases. Further research is needed to fully understand the role of TRIM16L in cellular processes and its potential as a drug target.

Protein Name: Tripartite Motif Containing 16 Like

The "TRIM16L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM16L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TRIM17 | TRIM2 | TRIM21 | TRIM22 | TRIM23 | TRIM24 | TRIM25 | TRIM26 | TRIM27 | TRIM28 | TRIM29 | TRIM3 | TRIM31 | TRIM32 | TRIM33 | TRIM34 | TRIM35 | TRIM36 | TRIM37 | TRIM38 | TRIM39 | TRIM39-RPP21 | TRIM4 | TRIM40 | TRIM41 | TRIM42 | TRIM43 | TRIM43B | TRIM44 | TRIM45 | TRIM46 | TRIM47 | TRIM48 | TRIM49 | TRIM49B | TRIM49C | TRIM49D2 | TRIM5 | TRIM50 | TRIM51 | TRIM51EP | TRIM51G | TRIM51HP | TRIM52 | TRIM53AP | TRIM54 | TRIM55 | TRIM56 | TRIM58 | TRIM59 | TRIM59-IFT80 | TRIM6 | TRIM6-TRIM34 | TRIM60 | TRIM60P15 | TRIM61 | TRIM62 | TRIM63 | TRIM64 | TRIM64B | TRIM64C | TRIM65 | TRIM66 | TRIM67 | TRIM68 | TRIM69 | TRIM7 | TRIM7-AS2 | TRIM71 | TRIM72 | TRIM73 | TRIM74 | TRIM75 | TRIM77 | TRIM8 | TRIM9 | TRIML1 | TRIML2 | TRIO | TRIOBP | TRIP10 | TRIP11 | TRIP12 | TRIP13 | TRIP4 | TRIP6 | Tripartite motif containing 78, pseudogene | TRIQK | TRIR | TRIT1 | TRL-AAG1-2 | TRL-AAG2-3 | TRL-TAG2-1 | TRMO | TRMT1 | TRMT10A | TRMT10B | TRMT10C | TRMT11 | TRMT112